Xiao-Jun Yu

Xiao-Jun Yu

Auto-generated profile, based on publicly available information

Xiao-Jun Yu

Department of Spine Surgery, Honghui Hospital, Xi’an Jiaotong University, Xi’an 710054, Shaanxi, China

Research Focus & Metrics

Academic Career Length

22Years (2005-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 July 2017 in Journal of Investigative Surgery
Verified
Journal Article
Closed access
XYXiao-Jun Yu
Xiao-Jun Yu
WDWan-Rong Dai
Wan-Rong Dai
YXYong Xu
Yong Xu
Objective: Treatment modalities in medically compromised patients with early-stage non-small cell lung cancer (NSCLC) are controversial. Stereotactic body radiotherapy (SBRT) or stereotactic ablative radiotherapy has been increasingly recognized as a favorable alternative to surgical resection for early-stage NSCLC. Many retrospective analyses compared the efficacy of stereotactic body radiotherapy (SBRT) with surgery for early-stage non-small cell lung cancer (NSCLC). However, the efficacy between SBRT and surgery regimens for patients with early-stage NSCLC remains unclear. This study aimed to investigate the efficacy between SBRT and surgery. Methods: Publications on comparison SBRT with Surgery in treatment of early stage non-small cell lung cancer (NSCLC) from 2011 to 2017 were collected. Retrospective trials analyzed the summary hazard ratios (HRs) of overall survival (OS), disease-free survival (DFS), local control survival (LC), regional control survival (RC), loco-regional control survival (LRC), and distant control survival (DC) between SBRT and Surgery. The major outcomes measures were hazard ratios (HRs). Meta-analysis Revman 5.3 software was used to analyze the combined Pooled HRs using fixed- or random-effects models according to the heterogeneity. Result: A systematic literature search was conducted including14 studies. In this meta-analysis, patients with SBRT achieved inferior OS, DFS, LC, RC, LRC and DC, compared with surgery. Conclusion: In this study we found more favorable outcomes with stage I NSCLC treated with SBRT. The surgery had no obvious advantages in this meta-analysis. Although surgery has become the recommended treatment at present, SBRT has potential to be an alternative treatment as a novel non-invasive radiation therapy modality in patients with stage I-II NSCLC.

2 April 2013 in Cell Biochemistry and Biophysics
Verified
Journal Article
Closed access
PDF file
XLXiao-Ping Lai
Xiao-Ping Lai
XYXiao-Jun Yu
Xiao-Jun Yu
HQHong Qian
Hong Qian
LWLai Wei
Lai Wei
JLJun-Yao Lv
Jun-Yao Lv
XXXiao-Hu Xu
Xiao-Hu Xu

30 July 2024 in ACS Biomaterials Science & Engineering
Verified
Journal Article
Closed access
XYXiao-Jun Yu
Xiao-Jun Yu
XBXiao-Fan Bai
Xiao-Fan Bai
YQYun-Kun Qu
Yun-Kun Qu
SWShan-Xi Wang
Shan-Xi Wang
JZJianwei Zhang
Jianwei Zhang
YZYuan-Ting Zhao
Yuan-Ting Zhao

15 January 2005 in Materials Science Forum
Verified
Journal Article
Closed access
PDF file
JHJimmy Hu
Jimmy Hu
HQHong Wei Qin
Hong Wei Qin
MJMinhua Jiang
Minhua Jiang
BLBo Li
Bo Li
Dongliang ZhaoDongliang Zhao
Dongliang Zhao
XWXin Lin Wang
Xin Lin Wang
FeCuNbSiB and FeZrBCu nanocrystalline ribbons can be obtained directly through the melt- spinning technique without additional annealing processes. The giant magnetoimpedance can be observed in FeCuNbSiB and FeZrBCu as quenched ribbons. The addition of Cu improves the nano-crystallization of a-Fe(Si) or a-Fe phase and reduces the grain size in FeCuNbSiB and FeZrBCu as quenched ribbons, which enhances the magnetoimpedance via increasing the variation of permeability under fields. The present experimental results reveal a novel route to fabricate the Fe based nanocrystalline soft magnetic materials with giant magnetoimpedance effect.

1 April 2007 in Biochemistry and Cell Biology
Verified
Journal Article
Closed access
HDHongmei Dong
Hongmei Dong
XXXiaohu Xu
Xiaohu Xu
MDMohong Deng
Mohong Deng
XYXiaojun Yu
Xiaojun Yu
HZHu Zhao
Hu Zhao
YGYiqun Geng
Yiqun Geng
The aim of the study was to prepare an active recombinant human perforin by comparing 5 candidate segments of human perforin. Full-length perforin, MAC1 (28–349 aa), MAC2 (166–369 aa), C-100, and N-60 of human perforin were selected as candidate active segments and designated, respectively, HP1, HP2, HP3, HP4, and HP5. The target genes were amplified by PCR and the products were individually subcloned into pGEM-T. The genes for HP1, HP2, HP3, and HP5 were subcloned into pET-DsbA, whereas pET-41a (+) was used as the expression vector of HP4. The fusion proteins were expressed in Escherichia coli BL21pLysS(DE3) and purified using nickel nitrilotriacetic acid (NTA) agarose affinity chromatography. The hemolysis microassay was used as an activity assay of fusion protein. From this study, we obtained the recombinant plasmids pGEM-T-HP1, -HP2, -HP3, -HP4 and -HP5, consisting of 1600, 960, 600, 300bp, and 180, respectively. From these recombinant plasmids, expression plasmids were successfully constructed and expressed in E. coli BL21pLysS(DE3). The resultant fusion proteins, affinity purified using Ni–NTA, were ~80, 58, 45, 44, and 30 kDa, respectively. The recombinant proteins were assayed for activity on hemolysis. HP2 and HP5 were the only recombinant proteins that were active in hemolysis, and the hemolytic function was concentration dependent. These results demonstrate that active recombinant forms of perforin can be synthesized in a prokaryote model. The recombinant N-60 and MAC1 (28–349 aa) of human perforin have the function of forming pores. Our study provides the experimental basis for further investigation on the application of perforin.